Terms: = Prostate cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Treatment
105 results:
1. The impact of transportation mode, socioeconomic deprivation and rurality on travel times to radiotherapy and surgical services for patients with prostate cancer: A national population-based evaluation.
Han L; Sullivan R; Tree A; Lewis D; Price P; Sangar V; van der Meulen J; Aggarwal A
Radiother Oncol; 2024 Mar; 192():110092. PubMed ID: 38219910
[TBL] [Abstract] [Full Text] [Related]
2. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing car T-cell therapy.
Voltin CA; Paccagnella A; Winkelmann M; Heger JM; Casadei B; Beckmann L; Herrmann K; Dekorsy FJ; Kutsch N; Borchmann P; Fanti S; Kunz WG; Subklewe M; Kobe C; Zinzani PL; Stelljes M; Roth KS; Drzezga A; Noppeney R; Rahbar K; Reinhardt HC; von Tresckow B; Seifert R; Albring JC; Blumenberg V; Farolfi A; Flossdorf S; Gödel P; Hanoun C
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1361-1370. PubMed ID: 38114616
[TBL] [Abstract] [Full Text] [Related]
3. Noninvasive longitudinal PET/CT imaging of car T cells using PSMA reporter gene.
Song X; Zhang Y; Lv X; Xu Z; Long Y; Gai Y; Jiang D; Lei P; Lan X
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):965-977. PubMed ID: 37971500
[TBL] [Abstract] [Full Text] [Related]
4. [Metastatic castration-resistant prostate cancer-emerging trends in therapy].
von Amsberg G; Todenhöfer T
Urologie; 2023 Dec; 62(12):1289-1294. PubMed ID: 37955661
[TBL] [Abstract] [Full Text] [Related]
5. Construction of truncated PSMA as a PET reporter gene for car T cell trafficking.
Zhang Y; Song X; Xu Z; Lv X; Long Y; Lan X; Lei P
J Leukoc Biol; 2024 Feb; 115(3):476-482. PubMed ID: 37943840
[TBL] [Abstract] [Full Text] [Related]
6. Strategies for modifying the chimeric antigen receptor (car) to improve safety and reduce toxicity in car T cell therapy for cancer.
Sayadmanesh A; Yekehfallah V; Valizadeh A; Abedelahi A; Shafaei H; Shanehbandi D; Basiri M; Baradaran B
Int Immunopharmacol; 2023 Dec; 125(Pt A):111093. PubMed ID: 37897950
[TBL] [Abstract] [Full Text] [Related]
7. Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients.
Cattrini C; Manfredi M; Barboro P; Ghirimoldi M; Mennitto A; Martini V; Battioni A; Le Van M; Gobbato S; Branni C; Ayed RB; Pinato DJ; Catalano F; Zanardi E; Boccardo F; Gennari A
Sci Rep; 2023 Oct; 13(1):17791. PubMed ID: 37853018
[TBL] [Abstract] [Full Text] [Related]
8. Emerging Immunotherapy Approaches for Treating prostate cancer.
Meng L; Yang Y; Mortazavi A; Zhang J
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762648
[TBL] [Abstract] [Full Text] [Related]
9. Pre-clinical validation of a pan-cancer car-T cell immunotherapy targeting nfP2X7.
Bandara V; Foeng J; Gundsambuu B; Norton TS; Napoli S; McPeake DJ; Tyllis TS; Rohani-Rad E; Abbott C; Mills SJ; Tan LY; Thompson EJ; Willet VM; Nikitaras VJ; Zheng J; Comerford I; Johnson A; Coombs J; Oehler MK; Ricciardelli C; Cowin AJ; Bonder CS; Jensen M; Sadlon TJ; McColl SR; Barry SC
Nat Commun; 2023 Sep; 14(1):5546. PubMed ID: 37684239
[TBL] [Abstract] [Full Text] [Related]
10. Tandem car-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer.
Wang A; Lv T; Song Y
Cell Immunol; 2023; 391-392():104760. PubMed ID: 37660477
[TBL] [Abstract] [Full Text] [Related]
11. Low-dose carboplatin modifies the tumor microenvironment to augment car T cell efficacy in human prostate cancer models.
Porter LH; Zhu JJ; Lister NL; Harrison SG; Keerthikumar S; Goode DL; Urban RQ; Byrne DJ; Azad A; Vela I; Hofman MS; Neeson PJ; Darcy PK; Trapani JA; Taylor RA; Risbridger GP
Nat Commun; 2023 Sep; 14(1):5346. PubMed ID: 37660083
[TBL] [Abstract] [Full Text] [Related]
12. C reactive protein/Albumin ratio as predictor of prognosis in castration resistant metastatic prostate cancer.
Lorigo J; Tavares Silva E; Pedroso Lima J; Quaresma V; Pedrosa R; Figueiredo A
Arch Ital Urol Androl; 2023 Jul; 95(3):11242. PubMed ID: 37435750
[TBL] [Abstract] [Full Text] [Related]
13. Low rates of primary medication nonadherence in patients prescribed oral oncology agents across health system specialty pharmacies.
Zuckerman A; Crumb J; Kandah HM; Platt T; Duckworth D; Lo K; Mitchell D; Diamantides E; Streck CM; DeClercq J; Choi L; Patel R
J Manag Care Spec Pharm; 2023 Jul; 29(7):740-748. PubMed ID: 37404071
[No Abstract] [Full Text] [Related]
14. Immunotherapy combinations for metastatic castration-resistant prostate cancer - failed trials and future aspects.
Slovin SF
Curr Opin Urol; 2023 Sep; 33(5):390-395. PubMed ID: 37395505
[TBL] [Abstract] [Full Text] [Related]
15. [New forms of immunotherapy in uro-oncology : HLA-independent therapeutic approaches with bispecific antibodies and car T cells].
Krebs M; Chatterjee M; Kübler H; Kalogirou C
Urologie; 2023 Jul; 62(7):685-690. PubMed ID: 37341719
[TBL] [Abstract] [Full Text] [Related]
16. CD24 targeting with NK-car immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners.
Söhngen C; Thomas DJ; Skowron MA; Bremmer F; Eckstein M; Stefanski A; Driessen MD; Wakileh GA; Stühler K; Altevogt P; Theodorescu D; Klapdor R; Schambach A; Nettersheim D
FEBS J; 2023 Oct; 290(20):4864-4876. PubMed ID: 37254618
[TBL] [Abstract] [Full Text] [Related]
17. γδ-Enriched car-T cell therapy for bone metastatic castrate-resistant prostate cancer.
Frieling JS; Tordesillas L; Bustos XE; Ramello MC; Bishop RT; Cianne JE; Snedal SA; Li T; Lo CH; de la Iglesia J; Roselli E; Benzaïd I; Wang X; Kim Y; Lynch CC; Abate-Daga D
Sci Adv; 2023 May; 9(18):eadf0108. PubMed ID: 37134157
[TBL] [Abstract] [Full Text] [Related]
18. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Bhatia V; Kamat NV; Pariva TE; Wu LT; Tsao A; Sasaki K; Sun H; Javier G; Nutt S; Coleman I; Hitchcock L; Zhang A; Rudoy D; Gulati R; Patel RA; Roudier MP; True LD; Srivastava S; Morrissey CM; Haffner MC; Nelson PS; Priceman SJ; Ishihara J; Lee JK
Nat Commun; 2023 Apr; 14(1):2041. PubMed ID: 37041154
[TBL] [Abstract] [Full Text] [Related]
19. Generation and Functional Characterization of PLAP car-T Cells against Cervical cancer Cells.
Yekehfallah V; Pahlavanneshan S; Sayadmanesh A; Momtahan Z; Ma B; Basiri M
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139135
[TBL] [Abstract] [Full Text] [Related]
20. Docetaxel enhances the therapeutic efficacy of PSMA-specific car-T cells against prostate cancer models by suppressing MDSCs.
Zhang X; Sun S; Miao Y; Yuan Y; Zhao W; Li H; Wei X; Huang C; Hu X; Wang B; Xu H; Zhang W; Gao X; Song J; Zheng J; Zhang Q
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3511-3520. PubMed ID: 35962287
[TBL] [Abstract] [Full Text] [Related]
[Next]
